Author/Authors :
Mohamed, Amal A Department of Biochemistry - National Hepatology & Tropical Medicine Research Institute, Egypt , Abd-Elsalam, Sherief Department of Tropical Medicine - Tanta University, Egypt , Zaghloul, Mariam Hepatology, Gastroenterology and Infectious diseases - Kafr-Elsheikh University, Egypt , Attala, Mohamed Department of Tropical - National Hepatology & Tropical Medicine Research Institute, Egypt , Khattab, Rania A Department of Microbiology and Immunology - Faculty of Pharmacy - Cairo University, Egypt , Khater, Amir Department of Tropical - National Hepatology & Tropical Medicine Research Institute, Egypt , El-damasy, Dalia A Department of Microbiology - Faculty of Pharmacy - Egyptian Russian University, Egypt , El-Sayed, Eman Department of Clinical Pathology - Faculty of Medicine - Minia University, Egypt , Hassanin, Soha Department of Biochemistry - Modern University for Technology and Information, Egypt , Hawash, Nehad Department of Tropical Medicine - Tanta University, Egypt , Mohamed, Mohmoud R. Internal Medicine - Faculty of Medicine - Minia University, Egypt
Abstract :
Background & Aims:
Several studies, in different populations, have focused on the role of HLA-DQ gene polymorphism in the pathogenesis of HBV infection. However, these findings are still controversial. This study aimed to determine HLA-DQ polymorphism in Chronic HBV patients and its impact on the response to antiviral therapy.
Methods:
This study was carried out on a total number of 188 participants, they were subdivided as follows: Group I (patients’ group): included 97 patients with chronic hepatitis B viral infection that was further subdivided according to response to treatment into responder and non-responder subgroups, Group II (Control group): included 91 normal healthy subjects who were matched to the patient group by sex and age. PCR (Polymerase Chain Reaction) testing, for HBV-DNA, was done for all participants enrolled in the study to measure the viral virus load before and after treatment. HLA- DQ polymorphism allelic discrimination assay was assayed using the Real-time equipment.
Results:
In a general analysis for the SNP rs7453920, the overall genotypes frequencies were 37% for A/A, 60.6% for A/G, and 37% for G/G. The G alleles of HLA-DQ rs7453920 were significantly increased in chronic HBV infection patients. A total of 77 (79.4%) patients were responders. Among this group, 72.7% were male, and the average age was 38.59 ±9.15 years. On evaluation of the association between polymorphisms in HLA-DQ gene and treatment response, the results indicated that response to treatment declined when patients were carrying the more unfavorable rs 7453920 GG with a response rate of 64%. Patients carrying the mutant allele AG, or the wild type allele AA were more likely to achieve a higher rate of response (84.8% and 83.3%, respectively).
Conclusion:
The presence of HLA-DQB2 rs 7453920-G serves as a risk factor for chronic HBV infection and treatment failure in the Egyptian population.
Keywords :
Hepatitis B virus , HLA-DQ , Antiviral therapy , Polymorphism , Response , PCR
